Sporadic clinical evidence also shows that anti-inflammatory neuropeptide mediators are able to delay the onset of RA, demonstrated by cases of rapidly developing RA immediately after the successful treatment of somatostatin-producing endocrine tumors17. The gene discussed is SST; the disease is rheumatoid arthritis.